Sustainability Report

Overview

The report presents TTY Biopharm's 2021 sustainability strategy, including Board-supervised sustainability governance, a five-step materiality process, and programs spanning responsible pharmaceuticals, environmental management, employee development, occupational safety, and community health. Consolidated revenue reached NTD$4,535,610 thousand and the reported full-time workforce totaled 542 employees. The two major manufacturing sites reported 66,490,946 million joules of energy consumption and 7,900 tonCO2e of GHG emissions, while total waste across the disclosed factories was about 45.02 tons. BSI reproduced an independent AA1000AS v3 Type 1 assurance opinion for the report.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2021
Period: 1 January 2021 – 31 December 2021
Publication date: 1 July 2022
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services

Overview